- Home
- NGNE vs OLP Comparison
NGNE vs OLP Comparison
Compare NGNE & OLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- OLP
- Stock Information
- Founded
- NGNE 2003
- OLP 1982
- Country
- NGNE United States
- OLP United States
- Employees
- NGNE N/A
- OLP N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- OLP Real Estate Investment Trusts
- Sector
- NGNE Health Care
- OLP Real Estate
- Exchange
- NGNE Nasdaq
- OLP Nasdaq
- Market Cap
- NGNE 426.6M
- OLP 478.2M
- IPO Year
- NGNE N/A
- OLP N/A
- Fundamental
- Price
- NGNE $33.14
- OLP $20.13
- Analyst Decision
- NGNE Strong Buy
- OLP
- Analyst Count
- NGNE 8
- OLP 0
- Target Price
- NGNE $42.25
- OLP N/A
- AVG Volume (30 Days)
- NGNE 255.8K
- OLP 77.3K
- Earning Date
- NGNE 11-14-2025
- OLP 11-03-2025
- Dividend Yield
- NGNE N/A
- OLP 9.01%
- EPS Growth
- NGNE N/A
- OLP N/A
- EPS
- NGNE N/A
- OLP 1.29
- Revenue
- NGNE N/A
- OLP $94,839,000.00
- Revenue This Year
- NGNE N/A
- OLP $8.83
- Revenue Next Year
- NGNE N/A
- OLP $2.91
- P/E Ratio
- NGNE N/A
- OLP $15.61
- Revenue Growth
- NGNE N/A
- OLP 7.07
- 52 Week Low
- NGNE $6.88
- OLP $19.80
- 52 Week High
- NGNE $74.49
- OLP $30.45
- Technical
- Relative Strength Index (RSI)
- NGNE 63.63
- OLP 29.07
- Support Level
- NGNE $30.52
- OLP $20.38
- Resistance Level
- NGNE $32.99
- OLP $20.94
- Average True Range (ATR)
- NGNE 3.33
- OLP 0.39
- MACD
- NGNE -0.14
- OLP -0.01
- Stochastic Oscillator
- NGNE 53.62
- OLP 22.75
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.